Flax Pond Capital LLC Takes Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

Flax Pond Capital LLC bought a new position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 48,721 shares of the company’s stock, valued at approximately $3,389,000. Structure Therapeutics accounts for 2.5% of Flax Pond Capital LLC’s investment portfolio, making the stock its 19th largest position. Flax Pond Capital LLC owned 0.07% of Structure Therapeutics as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. State of Wyoming bought a new position in Structure Therapeutics during the 2nd quarter valued at approximately $28,000. EverSource Wealth Advisors LLC grew its position in shares of Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after buying an additional 901 shares during the last quarter. CWM LLC grew its position in shares of Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 125 shares during the last quarter. ANTIPODES PARTNERS Ltd increased its stake in shares of Structure Therapeutics by 39.1% during the third quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock valued at $114,000 after buying an additional 1,146 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Structure Therapeutics during the fourth quarter valued at approximately $127,000. 91.78% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on GPCR. HC Wainwright dropped their price target on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, June 11th. Wolfe Research initiated coverage on shares of Structure Therapeutics in a research report on Thursday, March 26th. They set a “peer perform” rating on the stock. Canaccord Genuity Group began coverage on shares of Structure Therapeutics in a report on Monday, April 27th. They issued a “buy” rating and a $101.00 price objective for the company. Citizens Jmp dropped their target price on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research report on Friday, February 27th. Finally, William Blair reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Structure Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $106.75.

Structure Therapeutics Price Performance

GPCR opened at $44.51 on Friday. Structure Therapeutics Inc. Sponsored ADR has a 52 week low of $15.80 and a 52 week high of $94.90. The stock has a market cap of $3.16 billion, a PE ratio of -51.16 and a beta of -1.35. The business has a 50 day moving average of $42.71 and a 200-day moving average of $57.50.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.04. Equities analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.